Eagle Health Investments LP Purchases Shares of 187,413 Illumina, Inc. $ILMN

Eagle Health Investments LP purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 187,413 shares of the life sciences company’s stock, valued at approximately $32,953,000. Illumina makes up about 5.5% of Eagle Health Investments LP’s holdings, making the stock its 6th biggest position.

Other large investors also recently modified their holdings of the company. Empowered Funds LLC raised its holdings in Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after acquiring an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC bought a new position in Illumina in the second quarter valued at approximately $621,000. CW Advisors LLC acquired a new position in shares of Illumina during the 2nd quarter worth approximately $275,000. Marshall Wace LLP increased its position in shares of Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC raised its stake in shares of Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 783 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at $2,311,360. This represents a 3.35% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,415,351 shares of company stock valued at $255,966,311. 2.90% of the stock is currently owned by company insiders.

Illumina Stock Up 8.9%

Shares of ILMN opened at $205.00 on Thursday. The firm has a market cap of $30.95 billion, a P/E ratio of 38.25, a price-to-earnings-growth ratio of 2.65 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $207.00. The firm’s 50-day simple moving average is $185.90 and its 200 day simple moving average is $151.49.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the business posted $1.19 earnings per share. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analyst Ratings Changes

ILMN has been the subject of several recent analyst reports. Royal Bank Of Canada increased their price objective on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Canaccord Genuity Group lifted their price objective on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. Finally, Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research note on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and an average target price of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.